Author

Peiyao Cheng

Observed name: P Cheng

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5123471768

DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study

2026 · R Atreya, E Louis, et al. · Journal of Crohn s and Colitis · 1

Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: Interim results from phase 3 COMMAND open-label extension study

2026 · R Atreya, E Louis, et al. · Zeitschrift für Gastroenterologie

Su1638 EFFICACY AND SAFETY UP TO 3 YEARS OF RISANKIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM PHASE 3 COMMAND OPEN-LABEL EXTENSION STUDY

2026 · Raja Atreya, Edouard Louis, et al. · Gastroenterology

Su1638 EFFICACY AND SAFETY UP TO 3 YEARS OF RISANKIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM PHASE 3 COMMAND OPEN-LABEL EXTENSION STUDY

2026 · Raja Atreya, Edouard Louis, et al. · Gastrointestinal Endoscopy

Works count: 4

Citation count: 1

H-index: 1

I10-index: